Soska V
Vnitr Lek. 1999 Jul;45(7):438-40.
Fibrates are hypolipaemic agents with a broad spectrum of action and long-term safety. They reduce the cardiovascular mortality and morbidity and can induce also regression of coronary atherosclerosis. They lower the plasma concentration of total and LDL-cholesterol, triacylglycerols, and produce a rise of HDL-cholesterol. Moreover they can reduce the level of fibrinogen, lipoprotein/a/, PAI-1, uric acid and the concentration of highly atherogenic small dense LDL3. Their effect is mediated by activation of "peroxisome proliferator-activated receptors" (PPARs) in the cell nucleus. At present we find on the market second generation fibrates as well as modern micronized medicaments of the third generation. They are indicated for treatment of patients with hypertriglyceridaemia, combined hyperlipidaemia and diabetic dyslipidemia.
贝特类药物是具有广泛作用谱和长期安全性的降血脂药物。它们可降低心血管疾病的死亡率和发病率，还能促使冠状动脉粥样硬化消退。它们降低血浆总胆固醇和低密度脂蛋白胆固醇、三酰甘油的浓度，并使高密度脂蛋白胆固醇升高。此外，它们可降低纤维蛋白原、脂蛋白/a/、纤溶酶原激活物抑制剂-1、尿酸的水平以及高度致动脉粥样硬化的小而密低密度脂蛋白3的浓度。它们的作用是通过激活细胞核内的“过氧化物酶体增殖物激活受体”（PPARs）介导的。目前，市场上有第二代贝特类药物以及第三代现代微粉化药物。它们适用于治疗高甘油三酯血症、混合型高脂血症和糖尿病血脂异常患者。
